2010 Annual Meeting | Diagnosis and Management of Motor Neuron Disease: ALS

Date Saturday 04/09/11

Time 06:00 PM - 08:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Kick-Off Program

Director(s) Hiroshi Mitsumoto, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with the different diagnoses and work-up, including genetic testing, of both common and uncommon MNDs and learn about evidence-based treatment and management, along with research and clinical trial updates.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Recommended Audience Trainee, General Neurologist

Teaching Styles Case-based, Didactic, Interactive, Audience Participation

Event Timeline
05:45 PM - 08:00 PM		Reception
06:00 PM - 06:40 PM		Differential Diagnoses David A. Chad, MD, FAAN
06:40 PM - 07:10 PM		Care and Management of Patients with MNDs Hiroshi Mitsumoto, MD, FAAN
07:10 PM - 07:40 PM		Research and Clinical Trials Jinsy Andrews, MD, FAAN
07:40 PM - 08:00 PM		Questions and Answers

Faculty Disclosures
Hiroshi Mitsumoto, MD, FAAN	Dr. Mitsumoto has nothing to disclose.
Jinsy Andrews, MD, FAAN	Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as a Consultant for Cytokinetics. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Apellis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Revalasio . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amylyx. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AL-S Pharma. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Quralis . Dr. Andrews has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for Neurosense. Dr. Andrews has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Akava. The institution of Dr. Andrews has received research support from Amylyx. The institution of Dr. Andrews has received research support from Biogen . The institution of Dr. Andrews has received research support from Cytokinetics . The institution of Dr. Andrews has received research support from NIH . The institution of Dr. Andrews has received research support from Biohaven/Platform Trial. The institution of Dr. Andrews has received research support from Clene/Platform Trial . The institution of Dr. Andrews has received research support from Ra Pharma/Platform Trial . The institution of Dr. Andrews has received research support from Prilenia/Platform Trial . Dr. Andrews has received research support from ALS Association . Dr. Andrews has a non-compensated relationship as a Board of Trustee Member with ALS Association that is relevant to AAN interests or activities.
David A. Chad, MD, FAAN	No disclosure on file